Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth…
Adding recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment protocols in adolescent/young adult men with hypogonadotropic hypogonadism results in normal testicular growth and may hasten induction of spermatogenesis.
Margaret Zacharin, M.B.B.S., Matthew A. Sabin, Ph.D., Veena V. Nair, M.D., Preeti Dagabdhao, M.D.
Volume 98, Issue 4, Pages 836-842, October 2012
To assess effects on spermatogenesis of adding recombinant FSH (rFSH) to HCG treatment protocols for adolescent/young adult males with hypogonadotrophic hypogonadism (HH).
Observational descriptive study.
Outpatient clinics in Australia and India.
19 males with Hypogonadotrophic Hypogonadism (age 14.5–31 years).
Treatment with either HCG treatment alone (n=9; Group 1) or in combination with rFSH (n=10; Group 2), over 6-9 months.
Main Outcome Measures:
Combined testicular volume (CTV), and testosterone, Inhibin B, semen/urine analysis at 6 – 9 months.
There were no differences between groups for baseline variables or changes in CTV with treatment. Despite this, evidence of spermatogenesis was present in all Group 2 patients by 9 months [range 0.2 to 15×10653 /ml] compared with 3/9 patients in Group 1 [range 0 to <1x10654 /ml]; p=0.003. Whole group and subgroup analyses did not demonstrate significant correlations between age at onset of treatment and either CTV or sperm count. Conclusions:
Addition of rFSH to HCG treatment protocols in adolescent/young adult HH males results in normal testicular growth and may hasten induction of spermatogenesis.